General Information of Drug Transporter (DT)
DT ID DTD0095 Transporter Info
Gene Name SLC13A5
Transporter Name Sodium-coupled citrate transporter
Gene ID
284111
UniProt ID
Q86YT5
Post-Translational Modification of This DT
Overview ofSLC13A5 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-N-glycosylation X-Phosphorylation X-Phosphorylation X: Amino Acid

N-glycosylation

  Asparagine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC13A5 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

562

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC13A5 Asparagine 562 has the potential to affect its expression or activity.

Phosphorylation

  Serine

          8 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC13A5 [2], [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

3

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 3 has the potential to affect its expression or activity.

  PTM Phenomenon2

Have the potential to influence SLC13A5 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

6

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 6 has the potential to affect its expression or activity.

  PTM Phenomenon3

Have the potential to influence SLC13A5 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

9

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 9 has the potential to affect its expression or activity.

  PTM Phenomenon4

. [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

140

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 140 has the potential to affect its expression or activity.

  PTM Phenomenon5

Have the potential to influence SLC13A5 [5], [6]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

184

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 184 has the potential to affect its expression or activity.

  PTM Phenomenon6

Have the potential to influence SLC13A5 [7]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

424

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 424 has the potential to affect its expression or activity.

  PTM Phenomenon7

. [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

427

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 427 has the potential to affect its expression or activity.

  PTM Phenomenon8

. [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

430

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Serine 430 has the potential to affect its expression or activity.

  Tyrosine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC13A5 [3]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

7

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC13A5 Tyrosine 7 has the potential to affect its expression or activity.
References
1 Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009 Feb;8(2):651-61.
2 Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells. PLoS One. 2018 Jul 12;13(7):e0199349.
3 Characterization of native protein complexes and protein isoform variation using size-fractionation-based quantitative proteomics. Mol Cell Proteomics. 2013 Dec;12(12):3851-73.
4 15 years of PhosphoSitePlus?: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 2019;47(D1):D433-D441.
5 TiO2 with Tandem Fractionation (TAFT): An Approach for Rapid, Deep, Reproducible, and High-Throughput Phosphoproteome Analysis. J Proteome Res. 2018 Jan 5;17(1):710-721.
6 Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatol Res. 2017 Dec;47(13):1469-1483.
7 iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.